Table 2.
Summary of patients' clinical characteristics
| Characteristics | BELs (n = 106) | EC (n = 126) | p value |
|---|---|---|---|
| Age at diagnosis, years† | < 0.001* | ||
| ≤ 50 | 65 (61.3) | 42 (33.3) | |
| 51–64 | 34 (32.1) | 77 (61.1) | |
| ≥ 65 | 7 (6.6) | 7 (5.6) | |
| BMI, kg/m2† | 0.405 | ||
| ≤ 24.9 | 48 (45.3) | 49 (38.9) | |
| 25–29.9 | 42 (39.6) | 50 (39.7) | |
| ≥ 30 | 16 (15.1) | 27 (21.4) | |
| Menopausal status† | 0.065 | ||
| Premenopausal | 60 (56.6) | 56 (44.4) | |
| Postmenopausal | 46 (43.4) | 70 (55.6) | |
| Nulliparity† | 0.092 | ||
| No | 103 (97.2) | 116 (92.1) | |
| Yes | 3 (2.8) | 10 (7.9) | |
| Diabetes† | 0.698 | ||
| No | 99 (93.4) | 116 (92.1) | |
| Yes | 7 (6.6) | 10 (7.9) | |
| PCOS† | 0.358 | ||
| No | 106 (100) | 125 (99.2) | |
| Yes | 0 (0) | 1 (0.8) | |
| Long-term tamoxifen therapy† | 0.001* | ||
| No | 91 (85.8) | 123 (97.6) | |
| Yes | 15 (14.2) | 3 (2.4) | |
| CA125(+)† | 11 (10.4) | 14 (11.1) | 0.858 |
| CA199(+)† | 3 (2.8) | 11 (8.7) | 0.06 |
BELs, benign endometrial lesions; EC, endometrial cancer; BMI, body mass index; PCOS, polycystic ovary syndrome; CA125, cancer antigen 125; CA199, cancer antigen 199
†Data in parentheses are percentages. *p < 0.05